Neurocrine Biosciences, Inc. (NBIX), Monday announced data from the Phase 4 KINECT-PRO open-label study, evaluating patient-reported outcomes on the use of INGREZZA capsules in a tardive dyskinesia patient population reflective of real-world clinical practice.
The study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period.
The findings, presented at 2025 Psych Congress Elevate, show robust and clinically meaningful improvements in patients' physical functioning, social interactions and emotional well-being.
The company noted that individuals with milder uncontrolled movement severity also demonstrated negative impact by their tardive dyskinesia at baseline , and meaningful improvements across all severity levels.
Currently, Neurocrine's stock is trading at $122.01, down 0.82 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.